EQS-Adhoc: APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons

Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014

APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons

Monheim am Rhein, 10 July 2023. The Chief Executive Officer (CEO) of APONTIS PHARMA AG (APONTIS PHARMA or Company, Ticker APPH / ISIN DE000A3CMGM5), Karlheinz Gast, has informed the Supervisory Board today that he is resigning from his office for personal reasons with immediate effect and that he is leaving the Executive Board.

The Supervisory Board received and accepted Mr. Gast's resignation at its extraordinary meeting today. The service agreement with Mr. Gast will be canceled by mutual agreement.

At the same time, the Supervisory Board appointed Bruno Wohlschlegel as a member of the Executive Board and as CEO for a period of 2 years with an effective date 1 September 2023. Until then, Executive Board member Thomas Milz will manage the Company alone.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA press contact

CROSS ALLIANCE
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330